The Ubiquitin System, Disease and Drug Discovery

2008 ◽  
Author(s):  
Matthew Petroski
Keyword(s):  
Drug Discovery ◽  
System Disease ◽  
Ubiquitin System

scholarly journals The ubiquitin system, disease, and drug discovery

2008 ◽  
Vol 9 (Suppl 1) ◽  
pp. S7 ◽  
Author(s):  
Matthew D Petroski
Keyword(s):  
Drug Discovery ◽  
System Disease ◽  
Ubiquitin System

scholarly journals Targeting Cullin–RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation

2015 ◽  
Vol 467 (3) ◽  
pp. 365-386 ◽  
Author(s):  
Emil Bulatov ◽  
Alessio Ciulli
Keyword(s):  
Drug Discovery ◽  
Small Molecule ◽  
Ubiquitin Ligases ◽  
Ubiquitin Proteasome System ◽  
E3 Ubiquitin Ligases ◽  
Comprehensive Overview ◽  
Ubiquitin System ◽  
Ubiquitin Proteasome ◽  
New Gene ◽  
Structure Assembly

In the last decade, the ubiquitin–proteasome system has emerged as a valid target for the development of novel therapeutics. E3 ubiquitin ligases are particularly attractive targets because they confer substrate specificity on the ubiquitin system. CRLs [Cullin–RING (really interesting new gene) E3 ubiquitin ligases] draw particular attention, being the largest family of E3s. The CRLs assemble into functional multisubunit complexes using a repertoire of substrate receptors, adaptors, Cullin scaffolds and RING-box proteins. Drug discovery targeting CRLs is growing in importance due to mounting evidence pointing to significant roles of these enzymes in diverse biological processes and human diseases, including cancer, where CRLs and their substrates often function as tumour suppressors or oncogenes. In the present review, we provide an account of the assembly and structure of CRL complexes, and outline the current state of the field in terms of available knowledge of small-molecule inhibitors and modulators of CRL activity. A comprehensive overview of the reported crystal structures of CRL subunits, components and full-size complexes, alone or with bound small molecules and substrate peptides, is included. This information is providing increasing opportunities to aid the rational structure-based design of chemical probes and potential small-molecule therapeutics targeting CRLs.

scholarly journals The MALDI TOF E2/E3 ligase assay as an universal tool for drug discovery in the ubiquitin pathway

2017 ◽  
Author(s):  
Virginia De Cesare ◽  
Clare Johnson ◽  
Victoria Barlow ◽  
James Hastie ◽  
Axel Knebel ◽  
...  
Keyword(s):  
Drug Discovery ◽  
High Throughput ◽  
High Throughput Screening ◽  
E3 Ligase ◽  
Ubiquitin Pathway ◽  
E3 Ligases ◽  
Maldi Tof ◽  
Compound Libraries ◽  
Ubiquitin System ◽  
Conjugating Enzymes

AbstractIn many diseases, components of the ubiquitin system - such as E2/E3 ligases and deubiquitylases - are dysregulated. The ubiquitin system has therefore become an emergent target for the treatment of a number of diseases, including cancer, neurodegeneration and autoimmunity. Despite of the efforts in this field, primary screenings of compound libraries to individuate new potential therapeutic molecules targeting the ubiquitin pathway have been strongly limited by the lack of robust and fast high-throughput assays. Here we report the first label-free high-throughput screening (HTS) assay for ubiquitin E2 conjugating enzymes and E3 ligases based on Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight (MALDI TOF) mass spectrometry. The MALDI TOF E2/E3 assay allows us to test E2 conjugating enzymes and E3 ligases for their ubiquitin transfer activity, to identify E2/E3 active pairs, inhibitor potency and specificity and to screen compound libraries in vitro without synthesis of chemical or fluorescent probes. We demonstrate that the MALDI TOF E2/E3 assay is a universal tool for drug discovery screening in the ubiquitin pathway as it is suitable for working with all E3 ligase families and requires a reduced amount of reagents, compared to standard biochemical assays.

Sign in / Sign up

Export Citation Format

Share Document